MTNB · Matinas Biopharma Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | $85.0K | - | $2.24M | $3.37M | $3.45M | - |
| SG&A | $1.94M | - | $1.58M | $1.84M | $1.86M | - | $2.14M | $2.47M | $2.46M | - |
| Total Operating Expenses | $1.94M | - | $1.58M | $1.84M | $1.95M | - | $4.38M | $5.84M | $5.90M | - |
| D&A | $0 | - | $2.0K | $12.0K | $18.0K | - | $90.0K | $90.0K | $94.0K | - |
| Operating Income | ($1.94M) | - | ($1.58M) | ($1.84M) | ($1.95M) | - | ($4.38M) | ($5.84M) | ($5.90M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($1.92M) | - | ($1.53M) | ($5.25M) | ($1.66M) | - | ($4.28M) | ($5.72M) | ($5.82M) | - |
| EPS - Basic | ($0.30) | - | ($0.40) | ($1.03) | ($0.33) | - | ($0.85) | ($0.02) | ($0.03) | - |
| EPS - Diluted | ($0.30) | - | ($0.40) | ($1.03) | ($0.33) | - | ($0.85) | ($0.02) | ($0.03) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.40M | $4.00M | $5.43M | $6.53M | $6.92M | $7.28M | $10.29M | $4.22M | $1.07M | $4.79M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $712.0K | $315.0K | $80.0K | $167.0K | $282.0K | $95.0K | $349.0K | $238.0K | $473.0K | $514.0K |
| Current Assets | $2.81M | $4.08M | $5.65M | $7.27M | $7.55M | $8.03M | $11.74M | $15.29M | $10.29M | $15.54M |
| Total Assets | $5.87M | $7.21M | $9.70M | $11.42M | $12.04M | $12.64M | $20.58M | $24.36M | $19.61M | $25.10M |
| Current Liabilities | $2.13M | $1.46M | $1.50M | $1.78M | $2.25M | $2.67M | $2.12M | $2.39M | $2.00M | $2.62M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $2.85M | $2.38M | $3.23M | $3.75M | $5.76M | $5.05M | $4.80M | $5.26M | $5.05M | $5.86M |
| Stockholders' Equity | $3.02M | $4.83M | $6.46M | $7.67M | $6.27M | $7.59M | $15.78M | $19.10M | $14.56M | $19.25M |
| Retained Earnings | ($212.71M) | ($210.79M) | ($208.88M) | ($206.72M) | ($201.48M) | ($199.82M) | ($191.39M) | ($187.12M) | ($181.40M) | ($175.57M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.60M) | - | - | - | ($2.01M) | - | - | - | ($5.77M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | $2.00M | - |
| Financing Cash Flow | - | - | - | - | $1.65M | - | - | - | $53.0K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -32.7% | - | -15.8% | -45.9% | -13.8% | - | -20.8% | -23.5% | -29.7% | - |
| Return on equity | -63.6% | - | -23.7% | -68.3% | -26.4% | - | -27.1% | -29.9% | -40.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.32 | 2.79 | 3.78 | 4.07 | 3.35 | 3.01 | 5.53 | 6.39 | 5.15 | 5.93 |
| Quick ratio | 1.32 | 2.79 | 3.78 | 4.07 | 3.35 | 3.01 | 5.53 | 6.39 | 5.15 | 5.93 |
| Cash ratio | 1.13 | 2.73 | 3.64 | 3.66 | 3.07 | 2.73 | 4.85 | 1.76 | 0.54 | 1.83 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.94 | 1.49 | 1.50 | 1.49 | 1.92 | 1.67 | 1.30 | 1.28 | 1.35 | 1.30 |
| Liabilities / Assets | 0.49 | 0.33 | 0.33 | 0.33 | 0.48 | 0.40 | 0.23 | 0.22 | 0.26 | 0.23 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 0.5% | - | 64.0% | 68.5% | 67.0% | - | 28.6% | 5.2% | -5.7% | - |
| Net income growth (YoY) | -16.0% | - | 64.2% | 8.3% | 71.6% | - | 29.4% | 5.6% | -5.6% | - |
| EPS growth (YoY) | 9.1% | - | 52.9% | -5050.0% | -1000.0% | - | -2733.3% | 33.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -51.8% | -36.4% | -59.1% | -59.8% | -56.9% | -60.6% | -31.8% | -31.4% | -55.4% | -47.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2020-12-31.
Product / service
$125.0K totalCFFResearch Grant Revenue$125.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Matinas BioPharma Holdings against the 5 most active filers in the same SIC group.